PARP1 and glioblastoma: The in vitro radiosensitization data presented here are consistent with an ex vivo study demonstrating >90% inhibition of PARP activity at 50 nM olaparib23 and support the concept that meaningful radiosensitization of GBM may be achievable with clinically deliverable olaparib doses.